中国肿瘤临床
中國腫瘤臨床
중국종류림상
Chinese Journal of Clinical Oncology
2015年
20期
1002-1006
,共5页
去势抵抗型前列腺癌%雄激素受体%抗雄激素%分子机制
去勢牴抗型前列腺癌%雄激素受體%抗雄激素%分子機製
거세저항형전렬선암%웅격소수체%항웅격소%분자궤제
castration-resistant prostate cancer%androgen receptor%anti-androgen%molecular mechanisms
去势抵抗型前列腺癌（castration-resistant prostate cancer，CRPC）是指经内分泌治疗产生耐药并继续发展的致命性前列腺癌，雄激素受体（androgen receptor，AR）激活途径仍是这一阶段前列腺癌发展的驱动机制，因此抗雄激素治疗仍然是重要的治疗手段之一。虽然许多新型抗雄激素治疗药物在临床治疗中显示了显著的疗效，但同时耐药也频繁出现。本文就近年来几种主要抗雄激素治疗药物的作用及相应的耐药机制进行综述。
去勢牴抗型前列腺癌（castration-resistant prostate cancer，CRPC）是指經內分泌治療產生耐藥併繼續髮展的緻命性前列腺癌，雄激素受體（androgen receptor，AR）激活途徑仍是這一階段前列腺癌髮展的驅動機製，因此抗雄激素治療仍然是重要的治療手段之一。雖然許多新型抗雄激素治療藥物在臨床治療中顯示瞭顯著的療效，但同時耐藥也頻繁齣現。本文就近年來幾種主要抗雄激素治療藥物的作用及相應的耐藥機製進行綜述。
거세저항형전렬선암（castration-resistant prostate cancer，CRPC）시지경내분비치료산생내약병계속발전적치명성전렬선암，웅격소수체（androgen receptor，AR）격활도경잉시저일계단전렬선암발전적구동궤제，인차항웅격소치료잉연시중요적치료수단지일。수연허다신형항웅격소치료약물재림상치료중현시료현저적료효，단동시내약야빈번출현。본문취근년래궤충주요항웅격소치료약물적작용급상응적내약궤제진행종술。
Castration-resistant prostate cancer (CRPC) is the lethal form of prostate cancer with developed resistance to androgen deprivation therapy. However, anti-androgen therapy remains an important treatment option because androgen receptor activation is a major driver of the advanced phase of CRPC. Drug resistance is frequently manifested despite the development of various novel anti-an-drogens with significant clinical efficacy. This review introduces several drugs prevalently used to treat CRPC. The mechanisms of ac-tion and pathways to resistance of these drugs are also discussed.
